Loading…
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-178M | $-166M | $-161M | -54.1% | - | - |
| 2024 | $0M | $-94M | $-80M | $-70M | -31.2% | - | - |
| 2023 | $0M | $-75M | $-69M | $-56M | 45.3% | - | - |
| 2022 | $0M | $-37M | $-37M | $-44M | 43.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 36.91 | 74.59 | 94.31 | 177.53 |
| Operating Income | -36.91 | -74.59 | -94.31 | -177.53 |
| EBITDA | -36.91 | -74.59 | -94.31 | -177.53 |
| EBIT | -36.91 | -74.59 | -94.31 | -177.53 |
| Pretax Income | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income Common Stockholders | -36.91 | -69.33 | -80.49 | -166.31 |
| Total Expenses | 36.91 | 74.59 | 94.31 | 177.53 |
| Interest Income | 0 | 5.26 | 13.82 | 11.23 |
| Research And Development | 30.43 | 64.88 | 79 | 153.35 |
| Selling General And Administration | 6.47 | 9.71 | 15.30 | 24.18 |
| Normalized EBITDA | -36.91 | -74.59 | -94.31 | -177.53 |
| Normalized Income | -36.91 | -69.33 | -80.49 | -166.31 |
| Basic EPS | -1.15 | -2.17 | -2.56 | 0 |
| Diluted EPS | -1.15 | -2.17 | -2.56 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Interest Income | 0 | 5.26 | 13.82 | 11.23 |
| Net Income From Continuing And Discontinued Operation | -36.91 | -69.33 | -80.49 | -166.31 |
| Total Operating Income As Reported | -36.91 | -74.59 | -94.31 | -177.53 |
| Diluted Average Shares | 31.96 | 31.96 | 31.47 | 0 |
| Basic Average Shares | 31.96 | 31.96 | 31.47 | 0 |
| Diluted NI Availto Com Stockholders | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income Including Noncontrolling Interests | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Income Continuous Operations | -36.91 | -69.33 | -80.49 | -166.31 |
| Net Non Operating Interest Income Expense | 0 | 5.26 | 13.82 | 11.23 |
| Interest Income Non Operating | 0 | 5.26 | 13.82 | 11.23 |
| General And Administrative Expense | 6.47 | 9.71 | 15.30 | 24.18 |
| Other Gand A | 6.47 | 9.71 | 15.30 | 24.18 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ArriVent BioPharma, Inc.this co. | AVBP | $1.4B | - | 4.15 | -54.1% | - |
| Alphatec Holdings, Inc. | ATEC | $1.4B | - | 112.05 | -1153.7% | 95.59 |
| Bicara Therapeutics Inc. | BCAX | $1.4B | - | 2.89 | -34.4% | -6.30 |
| AtriCure, Inc. | ATRC | $1.4B | - | 2.77 | 0.0% | 114.65 |
| Biohaven Ltd. | BHVN | $1.4B | - |
| 23.47 |
| -1418.8% |
| -1.93 |
| NovoCure Limited | NVCR | $1.4B | - | 3.94 | -40.0% | -8.57 |
| Ardent Health, Inc. | ARDT | $1.4B | 10.03 | 1.07 | 8.1% | 7.02 |
| Pulse Biosciences, Inc. | PLSE | $1.4B | - | 17.00 | -90.2% | -17.15 |
| Viridian Therapeutics, Inc. | VRDN | $1.4B | - | 2.30 | -47.4% | -1.84 |
| Peer Median | - | 10.03 | 3.41 | -43.7% | -1.89 | |